OBJECTIVE To determine whether antibodies against high-density lipoprotein (aHDL) and apolipoprotein A-I (aApo A-I) interfere with the anti-atherogenic functions of high-density lipoprotein (HDL) and relate to disease activity and damage in SLE. METHODS Seventy-seven SLE patients were compared with an age- and sex-frequency matched control group. Immunoglobulin G (IgG) aHDL, IgG aApoA-I, solu...

OBJECTIVE To evaluate the prevalence of major haemolytic disease-severe autoimmune haemolytic anaemia and severe thrombocytopenia-and to assess when these features develop. We also sought to analyse the clinical and serological outcomes of patients with haemolytic anaemia and thrombocytopenia with systemic lupus erythematosus (SLE) as compared with patients without these cytopenias. METHODS W...

Background Secondary inefficacy characterized by infusion reactions and anti-drug antibodies occur in 14% of SLE patients treated with repeat rituximab courses(1). Obinutuzumab is a next-generation humanized type-2 anti-CD20 therapy licensed for hematological malignancies which may overcome this issue(2). Objectives We set out to evaluate the clinical efficacy safety obinutuzumab cohort resista...

Correspondence to Professor Jill Buyon; Jbuyonic@aol.com In clinical medicine, we seek to heal, and it is a long held tenet that a ‘response’ to treatment should be congruent between a strictly defined objective outcome and the physician’s perception of improvement. As we advance in our understanding of the pathogenesis of lupus and molecularly targeted therapies are being studied, pivotal FDA ...

Background SLE is a heterogeneous disease with diverse clinical presentations, and up to 70–80% of patients develop skin manifestations. 1–3 In SLE, plasmacytoid dendritic cells (pDCs), major source Type I interferon (IFN), accumulate in the skin. 4 Treatment BIIB059, humanized monoclonal antibody targeting blood cell antigen 2 (BDCA2) that expressed on pDCs, leads rapid internalization BDCA2 f...

Background SLE more commonly affects non-White populations who suffer higher disease activity and greater damage accrual. Objectives To describe differential response of patients with moderate-severe in the UK by ethnic background. Methods Patients commencing rituximab (RTX), belimumab or a standard care medication (SoC) for BILAG-BR were analysed over 12 months. Major clinical (MCR) was define...

Abstract Background/Aims A major limitation of biologic therapy is formation anti-drug antibodies (ADA). We previously demonstrated that ADA to rituximab are more prevalent in patients undergoing treatment for systemic lupus erythematosus (SLE) than rheumatoid arthritis and vasculitis, predict subsequent infusion reactions. However, little known regarding the long-term dynamics rituximab. In th...